DiaSorin
DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand
The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
DiaSorin to Acquire Luminex for $1.8B
DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.
Luminex Shares Surge on Rumor of Acquisition by DiaSorin
Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.
BARDA Provides Additional Funding to DiaSorin Molecular for COVID-19 Tests
The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.